Ridgefield’s Boehringer Ingelheim CEO Promises to combat Colorectal Cancer

Paul Fonteyne, Boehringer Ingelheim’s leader and CEO and chief executive officer of the American Cancer Society’s CEOs Against Cancer initiative, is promising to help increment colorectal-growth screening rates by supporting the “80% by 2018″ initiative.

The activity is driven by the American Cancer Society, the government Centers for Disease Control and Prevention and the National Colorectal Cancer Roundtable, an association co-founded by the ACS and the CDC.

According to Paul Fonteyne, Boehringer Ingelheim’s “We are thrilled to team up with the American Cancer Society and many other organizations to improve colorectal cancer screening rates nationwide,”

Paul Fonteyne Boehringer Ingelheim’s also stated “We are asking our members and their businesses to come together and help us talk to friends and family who are over 50 years of age about getting screened. Together, we can help reduce the impact of colorectal cancer as a major public health problem and ultimately save lives,”

Fonteyne is working with Robert Dickey, president of Randstad, Technologies & Engineering and current seat of CEOs Against Cancer, to rally the 32-part New England section of CEOs Against Cancer to advance colon-tumor mindfulness.

Colorectal cancer is the country’s second-leading reason for disease related passings; be that as it may it is one of just a couple of growths that can be anticipated. Through formal colorectal tumor screening, specialists can discover and uproot shrouded developments before they get to be harmful. Uprooting polyps can counteract cancer altogether.

In the National Colorectal Cancer Roundtable’s “80% by 2018,” initiative, almost 200 associations have focused on removing colorectal tumor as a noteworthy general wellbeing issue and are moving in the direction of the imparted objective of 80 percent of grown-ups age 50 and more established being frequently screened for colorectal cancer by 2018.

Colorectal cancer incidence in the U.S. in 2011, the last time data was taken, according to CDC was 135,260 diagnosed patients. Out of these, 51,783 patients died.


Leave a Reply

Your email address will not be published. Required fields are marked *